Skip to main content

Materialise

SoftwareLeuven, BelgiumFounded 1990· One of 350 Software companies tracked by AMPulse

Collaborative additive manufacturing (CO-AM) software platform for industrial production combined with contract 3D printing services and custom orthopedic/dental medical devices, enabling workflows from design through quality control.

CEO / Founder
Brigitte de Vet-Veithen (since January 1, 2024)
Team Size
1001-5000
Stage
Public
Total Funding
Publicly Traded
Latest Round
IPO
Key Investors
Wilfried Vancraen; Hilde Ingelaere; Public Markets

Technology & Products

Key Products

CO-AM Professional: Business-wide collaboration, centralized 3D file management, Magics data preparation automation; CO-AM NPI: Design-of-Experiments, toolpath engineering optimization, layer image analysis for process development; CO-AM Enterprise: End-to-end production control, compliance tracking, traceability; CO-AM Brix: Low-code automation and SDK environment for custom workflows; Magics: Industry-standard data repair and preparation software; 3-matic: Advanced CAD/engineering tool for scan-to-part workflows; Anatomical Data Mining (ADaM): AI-powered population-based anatomical insights for orthopedic/medical device development; Contract 3D printing services: Metal (titanium, aluminum, stainless steel), polymers (nylon, resin), rapid prototyping; Custom orthopedic & dental implants: Patient-specific and anatomically optimized devices

Technological Advantage

Magics is the industry-standard for data preparation (defensible through user base lock-in and data ecosystem). CO-AM ecosystem positions Materialise as an operating system for AM, similar to how PDM software works for traditional CAD. Medical segment provides regulatory moat (FDA approvals) and recurring device sales. Integrated software + manufacturing services enables superior customer outcomes vs. point solutions.

Differentiation

Value Proposition

Reduce time-to-market for custom parts by 70–80% (from 14 weeks to 3 days for aerospace brackets); lower production costs by 30–40% vs. traditional manufacturing; achieve regulatory compliance and production traceability with CO-AM Enterprise; accelerate medical device development with anatomical AI (ADaM) and automated process optimization.

How They Differentiate

Materialise's primary differentiation vs. hardware manufacturers (Stratasys, 3D Systems, Desktop Metal) is platform-agnostic software (works with any printer vendor) and deep manufacturing/medical expertise. vs. contract manufacturers (Protolabs, Shapeways): integrated software + services; medical device regulatory expertise (FDA). vs. software vendors (Autodesk): proprietary Magics ecosystem and decades of embedded domain knowledge in AM workflow optimization.

Market & Competition

Target Customers

Industrial manufacturers, aerospace OEMs, medical device companies, dental laboratories, contract manufacturers pursuing high-mix low-volume and series production

Industry Verticals

Aerospace & Defense (structural components, brackets, engine parts); Automotive (lightweighting, custom tooling, interior trim); Medical Devices (orthopedic implants, dental prosthetics, surgical guides); Consumer & Professional (customized products, jewelry); Industrial Manufacturing (prototyping, low-volume production)

Competitors

Stratasys / 3D Systems (software + hardware manufacturer, competing in services and medical); Desktop Metal (hardware + software + services, competing in manufacturing and dental); Protolabs (contract manufacturing services, broader portfolio including CNC); Autodesk / Netfabb (software competitor, acquired by Autodesk, competing in workflow); GE Additive (software and services, competing in industrial manufacturing)

Growth & Milestones

Growth Metrics

FY2025 annual revenue €267M (per corporate website); Q1 2026 revenue €66.3M (stable YoY); Q1 2026 Medical segment +6.7% to €33.2M; Q1 2026 gross margin improved to 57.2%; Adjusted EBITDA €8.0M; Net profit €1.8M (vs. net loss of €0.5M in Q1 2025); Net cash position €72.8M; Materialise Medical is fastest-growing segment.

Major Milestones

Founded 1990 (rapid prototyping service provider, University of Leuven spin-off); IPO June 2014 (NASDAQ: MTLS, €8M shares at $12/ADS, raised ~$96M); Launched CO-AM software platform (2024–2025); Brigitte de Vet-Veithen appointed CEO January 2024; Introduced CO-AM Brix low-code automation tool (Formnext 2025); Transferred RapidFit business to management team (closed April 2026); Transferred eyewear business to management team (announced May 2026)

Notable Customers

Aerospace OEMs (unnamed in sources, implied by aerospace-focused marketing); Kapstone Medical (orthopedic devices); Global Orthopaedic Technology (APEX implants); Cooksongold (jewelry/precious metals); Various industrial manufacturers and dental laboratories

https://materialise.com

Why this company matters

Materialise occupies a rare position in additive manufacturing: it is both the dominant independent software vendor and a regulated medical device manufacturer. Founded in 1990 as a University of Leuven spin-off, the company has outlasted most hardware rivals by staying platform-agnostic. Its CO-AM software suite — spanning Professional, NPI, Enterprise, and Brix low-code tiers — competes directly with Autodesk Netfabb and GE Additive, while its in-house contract printing and orthopedic implant business creates a recurring revenue stream that pure software vendors lack.

The core technological advantage is Magics, the de facto standard for metal and polymer LPBF data preparation. Magics' user base lock-in and file-format ecosystem make it difficult for competitors to displace. On top of that, Materialise layers 3-matic for scan-to-part engineering, ADaM anatomical AI for medical device design, and CO-AM Brix for custom workflow automation. The platform supports all major printer brands, a key differentiator against hardware-tied software from Stratasys, 3D Systems, and Desktop Metal.

Customer segments span aerospace OEMs (brackets, engine parts), automotive tier-1s (lightweighting, tooling), dental labs, and medical device companies. Named partners include Kapstone Medical, Global Orthopaedic Technology, and Cooksongold. The medical segment is the fastest-growing, up 18.7% in Q1 2025, driven by FDA-cleared patient-specific implants and surgical guides. This regulatory moat — combined with 488 granted patents — creates a defensible high-margin annuity that contract manufacturers like Protolabs cannot replicate.

The open question is whether CO-AM can achieve the same ecosystem lock-in as PDM/PLM software in traditional manufacturing. PTC's integration partnership is a positive signal, but adoption among small-to-mid-size job shops remains unproven. With 2024 revenue of €65.7M and a TTM of $290M, Materialise is profitable but growing modestly; its long-term value hinges on converting more of the installed Magics base to recurring CO-AM subscriptions.